Antithrombotic Strategies in Atrial Fibrillation. The XIX CONAREC Registry

pp. 210-216

Authors

  • Valentín Roel Argentine Council of Residents in Cardiology (CONAREC); Chief Resident Hospital Durand (CABA)
  • Juan A. Mourkazel Argentine Council of Residents in Cardiology (CONAREC); Chief Resident Fundación Favaloro (CABA)
  • Ezequiel J. Zaidel Argentine Council of Residents in Cardiology (CONAREC); Chief Resident Sanatorio Güemes
  • Matías A. Galli Argentine Council of Residents in Cardiology (CONAREC); Chief Resident Hospital Eva Perón (ex Castex) (Provincia de Buenos Aires)
  • Walter Da Rosa Argentine Council of Residents in Cardiology (CONAREC); Chief Resident Hospital Alta Complejidad (Formosa)
  • Rodolfo Leiva Argentine Council of Residents in Cardiology (CONAREC); Chief Resident Hospital del Centenario (Rosario)
  • Carolina Cicero Argentine Council of Residents in Cardiology (CONAREC); Resident Hospital Lagomaggiore (Mendoza)
  • Jorge Thierer Head of Heart Failure Hospital Universitario CEMIC (CABA); Full Member of the Argentine Society of Cardiology

DOI:

https://doi.org/10.7775/rac.es.v83.i3.5723

Keywords:

Atrial Fibrillation - Anticoagulation - Hemorrhage - Stroke

Abstract

Background: Atrial fibrillation (AF) represents the most common sustained arrhythmia. Treatment has evolved since the last survey performed in our setting, with a marked trend towards the use anticoagulation therapy, and the development of new anticoagulation drugs. However, Argentina lacks updated data about antithrombotic therapy or the use of novel oral anticoagulants (NOAC).


Objective: The aim of the study was to assess antithrombotic strategies in AF patients admitted for cardiovascular causes in centers with cardiology residency.


Methods: Between September and November 2013, 927 patients with at least one episode of atrial fibrillation within the last 12 months and hospitalized for cardiovascular causes in centers with cardiology residency were enrolled in the study.

 

Results: Median values (interquartile range) of CHADS2 and CHA2 DS2-VASc and HASBLED scores were: 2 (1-3), 3 (2-4) and 1 (1-2), respectively. At admission, only 54% of patients with history of AF without contraindication and CHADS2≥1 (n=253)
received anticoagulation therapy; 89% with dicoumarinic agents and only 26.5% in the therapeutic range. At discharge, anti coagulation rates increased up to 70%, and including all patients without contraindication, 59.74% received anticoagulation
therapy at discharge. Aspirin as single strategy was used in 26% of patients. The major reasons for not prescribing anticoagulants included contraindications (36%), social limitations (21%) and unknown reasons (14.8%). Stroke [OR 2.18 (95% CI 1.02-4.67); p=0.04], age [OR 1.01 (95% CI 1-1.03); p=0.009], hypertension [OR 1.54 (95% CI 0.99-2.41); p=0.05], heart failure [OR 1.68 (95% CI 1.1-2.55); p<0.01] and severe ventricular dysfunction [OR 4.99 (95% CI 1.71-14.55); p=0.003] were independent predictors of anticoagulation. High level of education was a predictor for the use of NOAC (OR 1.84, 95% CI 1.08-3.14).


Conclusions: The population of this survey performed in centers with cardiology residency has moderate thromboembolic risk and low bleeding risk. The rate of oral anticoagulation increased during hospitalization and high level of education was associated with the indication of NOAC.

Published

2015-06-30

Issue

Section

ORIGINAL ARTICLES

Most read articles by the same author(s)

<< < 6 7 8 9 10 11